Edwards Net Debt from 2010 to 2025

EW Stock

USD 70.95 0.05 0.07%

Edwards Lifesciences Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt is likely to outpace its year average in 2025. Net Debt is the total debt of Edwards Lifesciences Corp minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2000-03-31

Previous Quarter

-3 B

Current Value

-2.3 B

Quarterly Volatility

477.6 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Edwards Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edwards Lifesciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 92.8 M, Interest Expense of 11 M or Selling General Administrative of 1.9 B, as well as many indicators such as Price To Sales Ratio of 4.44, Dividend Yield of 0.0 or PTB Ratio of 4.78. Edwards financial statements analysis is a perfect complement when working with Edwards Lifesciences Valuation or Volatility modules.

Check out the analysis of Edwards Lifesciences Correlation against competitors.

Latest Edwards Lifesciences' Net Debt Growth Pattern

Below is the plot of the Net Debt of Edwards Lifesciences Corp over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Edwards Lifesciences' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edwards Lifesciences' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Edwards Net Debt Regression Statistics

	Arithmetic Mean	(375,933,750)
	Coefficient Of Variation	(208.60)
	Mean Deviation	516,396,406
	Median	(118,500,000)
	Standard Deviation	784,199,457
	Sample Variance	614968.8T
	Range	2.7B
	R-Value	(0.71)
	Mean Square Error	325487.1T
	R-Squared	0.51
	Significance	0
	Slope	(117,168,971)
	Total Sum of Squares	9224531.8T

Edwards Net Debt History

	2025	-2.2 B
	2024	-2.3 B
	2023	-449.1 M
	2022	-77.7 M
	2021	-172.5 M
	2020	-488.3 M
	2019	-500.3 M

Other Fundumenentals of Edwards Lifesciences Corp

Net Debt To E B I T D A

Edwards Lifesciences Net Debt component correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Net Receivables	Good Will	Total Liab	Total Current Assets	Net Debt	Accounts Payable	Long Term Debt	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Treasury Stock	Short Term Investments	Net Tangible Assets	Capital Surpluse	Long Term Investments	Long Term Debt Total	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.99	0.96	0.69	0.92	0.89	0.97	-0.85	0.66	0.32	-0.61	0.82	0.89	0.96	-0.21	-0.65	0.7	0.96	0.8	0.48	0.53	0.33	-0.02	0.85	0.86	0.82
Total Stockholder Equity	0.99		0.98	0.63	0.91	0.82	0.97	-0.89	0.65	0.25	-0.62	0.85	0.88	0.95	-0.3	-0.63	0.71	0.96	0.74	0.42	0.46	0.34	-0.01	0.88	0.88	0.82
Retained Earnings	0.96	0.98		0.58	0.83	0.75	0.96	-0.89	0.54	0.26	-0.52	0.81	0.86	0.91	-0.3	-0.68	0.74	0.92	0.7	0.34	0.49	0.41	-0.05	0.88	0.86	0.8
Net Receivables	0.69	0.63	0.58		0.61	0.77	0.58	-0.36	0.76	0.44	-0.57	0.28	0.77	0.79	0.36	-0.64	0.25	0.76	0.94	0.63	0.52	-0.03	-0.2	0.69	0.71	0.75
Good Will	0.92	0.91	0.83	0.61		0.84	0.86	-0.76	0.77	0.24	-0.76	0.89	0.79	0.88	-0.36	-0.4	0.48	0.87	0.73	0.44	0.38	0.23	0.0	0.75	0.79	0.72
Total Liab	0.89	0.82	0.75	0.77	0.84		0.84	-0.61	0.63	0.5	-0.5	0.6	0.82	0.87	0.11	-0.63	0.56	0.85	0.87	0.64	0.68	0.25	-0.03	0.64	0.67	0.7
Total Current Assets	0.97	0.97	0.96	0.58	0.86	0.84		-0.92	0.5	0.29	-0.49	0.83	0.81	0.89	-0.24	-0.62	0.79	0.9	0.72	0.32	0.54	0.4	0.05	0.83	0.85	0.72
Net Debt	-0.85	-0.89	-0.89	-0.36	-0.76	-0.61	-0.92		-0.36	-0.09	0.42	-0.86	-0.63	-0.74	0.44	0.44	-0.71	-0.74	-0.5	-0.05	-0.35	-0.45	-0.2	-0.78	-0.83	-0.57
Accounts Payable	0.66	0.65	0.54	0.76	0.77	0.63	0.5	-0.36		0.24	-0.86	0.5	0.76	0.77	-0.13	-0.4	0.04	0.76	0.74	0.64	0.22	-0.04	0.01	0.67	0.69	0.79
Long Term Debt	0.32	0.25	0.26	0.44	0.24	0.5	0.29	-0.09	0.24		-0.11	0.05	0.33	0.32	0.22	-0.7	0.25	0.35	0.6	0.42	0.93	0.39	-0.03	0.21	0.23	0.24
Short Term Debt	-0.61	-0.62	-0.52	-0.57	-0.76	-0.5	-0.49	0.42	-0.86	-0.11		-0.55	-0.63	-0.71	0.26	0.24	-0.07	-0.69	-0.58	-0.45	-0.11	0.22	-0.01	-0.56	-0.62	-0.66
Intangible Assets	0.82	0.85	0.81	0.28	0.89	0.6	0.83	-0.86	0.5	0.05	-0.55		0.59	0.7	-0.66	-0.23	0.58	0.7	0.44	0.09	0.21	0.4	0.03	0.73	0.75	0.53
Common Stock	0.89	0.88	0.86	0.77	0.79	0.82	0.81	-0.63	0.76	0.33	-0.63	0.59		0.96	-0.05	-0.76	0.49	0.95	0.79	0.67	0.48	0.19	-0.04	0.8	0.77	0.97
Property Plant Equipment	0.96	0.95	0.91	0.79	0.88	0.87	0.89	-0.74	0.77	0.32	-0.71	0.7	0.96		-0.11	-0.7	0.57	0.99	0.84	0.61	0.5	0.2	-0.04	0.85	0.84	0.91
Current Deferred Revenue	-0.21	-0.3	-0.3	0.36	-0.36	0.11	-0.24	0.44	-0.13	0.22	0.26	-0.66	-0.05	-0.11		-0.21	-0.18	-0.13	0.17	0.29	0.24	-0.28	-0.13	-0.29	-0.28	-0.08
Treasury Stock	-0.65	-0.63	-0.68	-0.64	-0.4	-0.63	-0.62	0.44	-0.4	-0.7	0.24	-0.23	-0.76	-0.7	-0.21		-0.5	-0.73	-0.72	-0.59	-0.81	-0.43	0.03	-0.58	-0.53	-0.69
Short Term Investments	0.7	0.71	0.74	0.25	0.48	0.56	0.79	-0.71	0.04	0.25	-0.07	0.58	0.49	0.57	-0.18	-0.5		0.62	0.43	0.17	0.49	0.3	-0.08	0.61	0.56	0.42
Net Tangible Assets	0.96	0.96	0.92	0.76	0.87	0.85	0.9	-0.74	0.76	0.35	-0.69	0.7	0.95	0.99	-0.13	-0.73	0.62		0.84	0.62	0.52	0.22	-0.02	0.86	0.84	0.91
Capital Surpluse	0.8	0.74	0.7	0.94	0.73	0.87	0.72	-0.5	0.74	0.6	-0.58	0.44	0.79	0.84	0.17	-0.72	0.43	0.84		0.63	0.7	0.14	-0.17	0.76	0.77	0.74
Long Term Investments	0.48	0.42	0.34	0.63	0.44	0.64	0.32	-0.05	0.64	0.42	-0.45	0.09	0.67	0.61	0.29	-0.59	0.17	0.62	0.63		0.43	-0.02	-0.13	0.32	0.25	0.63
Long Term Debt Total	0.53	0.46	0.49	0.52	0.38	0.68	0.54	-0.35	0.22	0.93	-0.11	0.21	0.48	0.5	0.24	-0.81	0.49	0.52	0.7	0.43		0.48	0.0	0.36	0.38	0.35
Short Long Term Debt	0.33	0.34	0.41	-0.03	0.23	0.25	0.4	-0.45	-0.04	0.39	0.22	0.4	0.19	0.2	-0.28	-0.43	0.3	0.22	0.14	-0.02	0.48		0.09	0.22	0.21	0.07
Cash And Equivalents	-0.02	-0.01	-0.05	-0.2	0.0	-0.03	0.05	-0.2	0.01	-0.03	-0.01	0.03	-0.04	-0.04	-0.13	0.03	-0.08	-0.02	-0.17	-0.13	0.0	0.09		-0.11	0.01	-0.06
Net Invested Capital	0.85	0.88	0.88	0.69	0.75	0.64	0.83	-0.78	0.67	0.21	-0.56	0.73	0.8	0.85	-0.29	-0.58	0.61	0.86	0.76	0.32	0.36	0.22	-0.11		0.97	0.83
Net Working Capital	0.86	0.88	0.86	0.71	0.79	0.67	0.85	-0.83	0.69	0.23	-0.62	0.75	0.77	0.84	-0.28	-0.53	0.56	0.84	0.77	0.25	0.38	0.21	0.01	0.97		0.78
Capital Stock	0.82	0.82	0.8	0.75	0.72	0.7	0.72	-0.57	0.79	0.24	-0.66	0.53	0.97	0.91	-0.08	-0.69	0.42	0.91	0.74	0.63	0.35	0.07	-0.06	0.83	0.78

Click cells to compare fundamentals

About Edwards Lifesciences Financial Statements

Edwards Lifesciences investors use historical fundamental indicators, such as Edwards Lifesciences' Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edwards Lifesciences. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	-2.3 B	-2.2 B
Net Debt To EBITDA	(1.36)	(1.29)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
S	SentinelOne
GM	General Motors

Additional Tools for Edwards Stock Analysis

When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Edwards Net Debt from 2010 to 2025

Latest Edwards Lifesciences' Net Debt Growth Pattern

Edwards Net Debt Regression Statistics

Edwards Net Debt History

Other Fundumenentals of Edwards Lifesciences Corp

Edwards Lifesciences Net Debt component correlations

About Edwards Lifesciences Financial Statements

Also Currently Popular

Additional Tools for Edwards Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY